Phentermine
Centrally Acting Antiobesity Products
Sold as QUSIVA · IONAMIN 30 · IONAMIN 15
- Drug class
- Centrally Acting Antiobesity Products
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 2
- Products on record
- 17
Overview
Phentermine is an active pharmaceutical ingredient in the Centrally Acting Antiobesity Products group (A08AA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 12 | January 22, 2026 |
| GB United Kingdom | MHRA | 5 | February 25, 2025 |
USUnited States· FDA
12 products
Uses
, controlled hypertension, diabetes, hyperlipidemia). Below is a chart of body mass index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared.
0254 = meters. 2) ] should be measured against possible risk factors inherent in their use such as those described below. , controlled hypertension, diabetes, hyperlipidemia). ( 1 ) The limited usefulness of agents of this class, including phentermine hydrochloride, should be measured against possible risk factors inherent in their use.
( 1 ) Figure
How to take
GBUnited Kingdom· MHRA
5 products
Uses
Ionamin is an anorectic agent intended as an adjunctive therapy to diet in patients with obesity and a body mass index (BMI) of 30 kg/m2 or higher, who have not responded to an appropriate weight reducing regimen alone.
Note:
Short term efficacy only has been demonstrated with regard to weight reduction. No significant data on changes in morbidity or mortality are yet available.
How to take
Drug interactions
Known interactions involving Phentermine. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 02b8f684-b1ca-4a… · revised July 14, 2025 [PDF]
- [2]MHRA (UK) · PL005510225 · revised November 11, 2022
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.